Page 3 - Term Efficacy News Today

16 presentations will examine safety and efficacy of AJOVY and AUSTEDOTEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for two of the company’s neurology portfolio treatments, AJOVY® (fr...

Maximally sustaining IL-6 suppression in a chronic disease like NMOSD and enabling subcutaneous dosing every four weeks. Positive Phase III results for ENSPRYNG, as both monotherapy and in... | March 25, 2022

First data showing OCREVUS treatment effect on disability progression in non-active secondary progressive multiple sclerosis and further data in primary progressive MS will be presentedEvrysdi data continue

-Symposium on oral GnRH antagonists and personalized therapeutic approaches for women with uterine fibroids to be hosted Friday, December 10 at 1 p.m. CET- -52-Week Data from the Phase 3 PRIMROSE

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

/PRNewswire/ -- Eisai Inc. presented data from PERMIT, a large real-world clinical study evaluating its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII,...

/PRNewswire/ -- Eisai Inc. presented data from PERMIT, a large real-world clinical study evaluating its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII,...

/PRNewswire/ -- Eisai Inc. announced today that new data on its antiepileptic drug FYCOMPA® (perampanel) CIII will be presented at the 75th American Epilepsy...

/PRNewswire/ -- Eisai Inc. announced today that new data on its antiepileptic drug FYCOMPA® (perampanel) CIII will be presented at the 75th American Epilepsy...

The Russian-made Sputnik V Covid vaccine has demonstrated high long-term efficacy, according to data collected in San Marino. The jab remains around 80% ef